We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serum Folate Deficiency in Older People Associated With Heightened Dementia

By LabMedica International staff writers
Posted on 21 Mar 2022
Print article
Image: Low levels of folate (vitamin B9) in the blood may be linked to a heightened risk of dementia and death from any cause in older people (Photo courtesy of Regional Neurological Associates)
Image: Low levels of folate (vitamin B9) in the blood may be linked to a heightened risk of dementia and death from any cause in older people (Photo courtesy of Regional Neurological Associates)

With ageing, serum concentrations of folate decrease, leading to a higher prevalence of a threshold-based medical condition termed serum folate deficiency. The highest folate deficiency rates in the population occur among older adults, with estimated prevalence rates ranging from 5% to 20%.

Evidence suggests that serum folate deficiency increases the likelihood of deficits in cognitive performance and neurological functioning. This positions serum folate as a possible biomarker to modify the risk of dementia. However, the few observational studies that have examined the association between serum folate deficiency and the risk of dementia have shown inconsistent results.

A team of mental health professionals led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) examined the associations between serum folate deficiency and the risks of incident dementia and all-cause mortality in a large national sample of older adults. A prospective cohort of 27,188 aged 60–75 years without pre-existing dementia for at least 10 years was tested for serum concentrations of folate and followed up for dementia or all-cause mortality. Serum folate deficiency was classified as present or absent.

Serum folate is a direct measure of vitamin B9 in the blood and may therefore function as a biomarker (i.e., an objectively measured indicator). Serum concentrations of folate were measured using chemiluminescent microparticle immunoassay technology and derived from the clinical biochemistry electronic health records (EHRs). Measurements were ascertained as needed based on clinical impressions of the treating physician from 1 January 2013 to 30 October 2017.

The team reported that 3,418 (just under 13%) participants were folate deficient, defined as levels below 4.4 ng/mL. Folate deficiency was associated with a substantially heightened risk of both dementia and death from any cause. Among those who were folate deficient, the incidence of dementia was estimated at 7.96/10,000 person years, while death from any cause was estimated at 19.2/10,000 person years. This compares with an estimated dementia incidence of 4.24 and of death from any cause of 5.36/10,000 person years among those who weren't folate deficient.

The authors concluded that serum concentrations of folate may function as a biomarker used to modify the risks of dementia and mortality in old age, adding that older adults should be routinely screened for folate deficiency. The implications for public health policy appear to be to reliably monitor serum concentrations of folate in older adults and treat deficiency for preventative measures and/or as part of implemented therapeutic strategies while regularly reviewing patients' clinical outcomes. The study was published on March 15, 2022 in the journal Evidence-Based Mental Health.

Related Links:
Icahn School of Medicine at Mount Sinai 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
New
ELISA & CLIA Analyzer
Autoplex Gen2
New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.